{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:15:48Z","timestamp":1781774148937,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10330022010009"],"award-info":[{"award-number":["10330022010009"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10330022010009"],"award-info":[{"award-number":["10330022010009"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["NKI 2011-5270"],"award-info":[{"award-number":["NKI 2011-5270"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s11764-024-01561-y","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T23:50:51Z","timestamp":1713829851000},"page":"1419-1430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular screening outcomes in the Dutch survivorship care program for Hodgkin lymphoma survivors"],"prefix":"10.1007","volume":"19","author":[{"given":"Eline M. J.","family":"Lammers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Nijdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9e M.","family":"Zijlstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile P. M.","family":"Janus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel J.","family":"de Weijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande","family":"Appelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier C.","family":"Manintveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arco J.","family":"Teske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora E.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthe M. P.","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"issue":"8","key":"1561_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nrclinonc.2012.91","volume":"9","author":"P Borchmann","year":"2012","unstructured":"Borchmann P, Eichenauer DA, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol. 2012;9(8):450\u20139. https:\/\/doi.org\/10.1038\/nrclinonc.2012.91.","journal-title":"Nat Rev Clin Oncol"},{"key":"1561_CR2","doi-asserted-by":"publisher","unstructured":"Eichenauer DA, Aleman BMP, Andre M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv19\u201329. https:\/\/doi.org\/10.1093\/annonc\/mdy080.","DOI":"10.1093\/annonc\/mdy080"},{"issue":"3","key":"1561_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.seminhematol.2016.05.008","volume":"53","author":"AK Ng","year":"2016","unstructured":"Ng AK, van Leeuwen FE. Hodgkin lymphoma: late effects of treatment and guidelines for surveillance. Semin Hematol. 2016;53(3):209\u201315. https:\/\/doi.org\/10.1053\/j.seminhematol.2016.05.008.","journal-title":"Semin Hematol"},{"issue":"6","key":"1561_CR4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/bjc.2017.476","volume":"118","author":"S de Vries","year":"2018","unstructured":"de Vries S, Schaapveld M, van Nimwegen FA, Jozwiak K, Lugtenburg PJ, Daniels LA, et al. High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors. Br J Cancer. 2018;118(6):887\u201395. https:\/\/doi.org\/10.1038\/bjc.2017.476.","journal-title":"Br J Cancer"},{"issue":"5","key":"1561_CR5","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","volume":"109","author":"BM Aleman","year":"2007","unstructured":"Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van \u2019t Veer MB, Baaijens MH, de Boer JP, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878\u201386. https:\/\/doi.org\/10.1182\/blood-2006-07-034405.","journal-title":"Blood."},{"issue":"6","key":"1561_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","volume":"175","author":"FA van Nimwegen","year":"2015","unstructured":"van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007\u201317. https:\/\/doi.org\/10.1001\/jamainternmed.2015.1180.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"1561_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280\u201399. https:\/\/doi.org\/10.1093\/eurheartj\/ehab674.","journal-title":"Eur Heart J"},{"issue":"8","key":"1561_CR8","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1080\/10428190802140873","volume":"49","author":"S Myrehaug","year":"2008","unstructured":"Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49(8):1486\u201393. https:\/\/doi.org\/10.1080\/10428190802140873.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1561_CR9","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaoncol.2018.6634","volume":"5","author":"EAM Feijen","year":"2019","unstructured":"Feijen EAM, Leisenring WM, Stratton KL, Ness KK, van der Pal HJH, van Dalen EC, et al. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol. 2019;5(6):864\u201371. https:\/\/doi.org\/10.1001\/jamaoncol.2018.6634.","journal-title":"JAMA Oncol"},{"issue":"24","key":"1561_CR10","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1200\/JCO.2006.09.7451","volume":"25","author":"MM Hudson","year":"2007","unstructured":"Hudson MM, Rai SN, Nunez C, Merchant TE, Marina NM, Zalamea N, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol. 2007;25(24):3635\u201343. https:\/\/doi.org\/10.1200\/JCO.2006.09.7451.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1561_CR11","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1016\/j.ejca.2006.08.005","volume":"42","author":"EC van Dalen","year":"2006","unstructured":"van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. 2006;42(18):3191\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2006.08.005.","journal-title":"Eur J Cancer"},{"issue":"Suppl 11","key":"1561_CR12","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/cncr.28068","volume":"119","author":"MS McCabe","year":"2013","unstructured":"McCabe MS, Faithfull S, Makin W, Wengstrom Y. Survivorship programs and care planning. Cancer. 2013;119(Suppl 11):2179\u201386. https:\/\/doi.org\/10.1002\/cncr.28068.","journal-title":"Cancer"},{"issue":"8","key":"1561_CR13","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3324\/haematol.2014.104059","volume":"99","author":"T Barbui","year":"2014","unstructured":"Barbui T, Bjorkholm M, Gratwohl A. Cancer survivorship programs: time for concerted action. Haematologica. 2014;99(8):1273\u20136. https:\/\/doi.org\/10.3324\/haematol.2014.104059.","journal-title":"Haematologica"},{"issue":"4","key":"1561_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/bjh.15936","volume":"186","author":"A Nijdam","year":"2019","unstructured":"Nijdam A, Dekker N, Aleman BMP, van \u2018t Veer MB, Daniels LA, van der Maazen RW, et al. Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphoma. Br J Haematol. 2019;186(4):103\u20138. https:\/\/doi.org\/10.1111\/bjh.15936.","journal-title":"Br J Haematol."},{"key":"1561_CR15","unstructured":"Dutch society for Radiation Therapy and Oncology (NVRO). Cardiovascular adverse effects after Hodgkin lymphoma. 2016. https:\/\/richtlijnendatabase.nl\/richtlijn\/cardiovasculaire_schade_na_hodgkinlymfoom\/cardiovasculaire_hodgkinlymfoom_-_startpagina.html#:~:text=Zo%20kan%20bestraling%20en%20chemotherapie,ontwikkelen%20van%20hart%2D%20en%20vaatziekten. Accessed 3 July 2023."},{"issue":"23","key":"1561_CR16","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/j.jacc.2015.04.013","volume":"65","author":"GT Armstrong","year":"2015","unstructured":"Armstrong GT, Joshi VM, Ness KK, Marwick TH, Zhang N, Srivastava D, et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude lifetime cohort study. J Am Coll Cardiol. 2015;65(23):2511\u201322. https:\/\/doi.org\/10.1016\/j.jacc.2015.04.013.","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"1561_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaccao.2022.12.010","volume":"5","author":"C Palmer","year":"2023","unstructured":"Palmer C, Mazur W, Truong V, Nagueh S, Fowler J, Shelton K, et al. Prevalence of diastolic dysfunction in adult survivors of childhood cancer. J Am Coll Cardiol CardioOnc. 2023;5(3):377\u201388. https:\/\/doi.org\/10.1016\/j.jaccao.2022.12.010.","journal-title":"J Am Coll Cardiol CardioOnc"},{"key":"1561_CR18","unstructured":"American College of Cardiology. Left ventricular ejection fraction LVEF assessment (outpatient setting). https:\/\/www.acc.org\/tools-and-practice-support\/clinical-toolkits\/~\/media\/1E4D8F9B69D14F55821BFE642FBFA221.ashx. Accessed 3 July 2023."},{"issue":"12","key":"1561_CR19","doi-asserted-by":"publisher","first-page":"e024735","DOI":"10.1161\/JAHA.121.024735","volume":"11","author":"EJ Chow","year":"2022","unstructured":"Chow EJ, Chen Y, Armstrong GT, Baldwin LM, Cai CR, Gibson TM, et al. Underdiagnosis and undertreatment of modifiable cardiovascular risk factors among survivors of childhood cancer. J Am Heart Assoc. 2022;11(12):e024735. https:\/\/doi.org\/10.1161\/JAHA.121.024735.","journal-title":"J Am Heart Assoc"},{"key":"1561_CR20","unstructured":"Tijn-A-Ton JJS, Konings KTS. Dutch college of general practioners (NHG) guideline cardiovascular risk management version 4.0. https:\/\/richtlijnen.nhg.org\/standaarden\/cardiovasculair-risicomanagement. Accessed 3 July 2023."},{"issue":"6","key":"1561_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/fampra\/cmm052","volume":"24","author":"PG Janssen","year":"2007","unstructured":"Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Low yield of population-based screening for Type 2 diabetes in the Netherlands: the ADDITION Netherlands study. Fam Pract. 2007;24(6):555\u201361. https:\/\/doi.org\/10.1093\/fampra\/cmm052.","journal-title":"Fam Pract"},{"issue":"4","key":"1561_CR22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/s0735-1097(03)00759-9","volume":"42","author":"PA Heidenreich","year":"2003","unstructured":"Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42(4):743\u20139. https:\/\/doi.org\/10.1016\/s0735-1097(03)00759-9.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1561_CR23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/sj.bjc.6605191","volume":"101","author":"T Wethal","year":"2009","unstructured":"Wethal T, Lund MB, Edvardsen T, Fossa SD, Pripp AH, Holte H, et al. Valvular dysfunction and left ventricular changes in Hodgkin\u2019s lymphoma survivors. A longitudinal study Br J Cancer. 2009;101(4):575\u201381. https:\/\/doi.org\/10.1038\/sj.bjc.6605191.","journal-title":"A longitudinal study Br J Cancer"},{"issue":"5","key":"1561_CR24","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1161\/CIR.0000000000000923","volume":"143","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e72\u2013227. https:\/\/doi.org\/10.1161\/CIR.0000000000000923.","journal-title":"Circulation"},{"issue":"17","key":"1561_CR25","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):1757\u201380. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.011.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1561_CR26","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1161\/01.CIR.0000085166.44904.79","volume":"108","author":"TJ Wang","year":"2003","unstructured":"Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108(8):977\u201382. https:\/\/doi.org\/10.1161\/01.CIR.0000085166.44904.79.","journal-title":"Circulation"},{"issue":"2","key":"1561_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.7326\/M15-0424","volume":"164","author":"DA Mulrooney","year":"2016","unstructured":"Mulrooney DA, Armstrong GT, Huang S, Ness KK, Ehrhardt MJ, Joshi VM, et al. Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy: a cross-sectional study. Ann Intern Med. 2016;164(2):93\u2013101. https:\/\/doi.org\/10.7326\/M15-0424.","journal-title":"Ann Intern Med"},{"key":"1561_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeac106","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022. https:\/\/doi.org\/10.1093\/ehjci\/jeac106.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"8","key":"1561_CR29","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.carrev.2018.07.021","volume":"19","author":"S Wu","year":"2018","unstructured":"Wu S, Chai A, Arimie S, Mehra A, Clavijo L, Matthews RV, et al. Incidence and treatment of severe primary mitral regurgitation in contemporary clinical practice. Cardiovasc Revasc Med. 2018;19(8):960\u20133. https:\/\/doi.org\/10.1016\/j.carrev.2018.07.021.","journal-title":"Cardiovasc Revasc Med"},{"issue":"3","key":"1561_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jcmg.2015.06.028","volume":"9","author":"K Murbraech","year":"2016","unstructured":"Murbraech K, Wethal T, Smeland KB, Holte H, Loge JH, Holte E, et al. Valvular dysfunction in lymphoma survivors treated with autologous stem cell transplantation: a national cross-sectional study. JACC Cardiovasc Imaging. 2016;9(3):230\u20139. https:\/\/doi.org\/10.1016\/j.jcmg.2015.06.028.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1561_CR31","doi-asserted-by":"publisher","first-page":"l6794","DOI":"10.1136\/bmj.l6794","volume":"368","author":"DA Mulrooney","year":"2020","unstructured":"Mulrooney DA, Hyun G, Ness KK, Ehrhardt MJ, Yasui Y, Duprez D, et al. Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort. BMJ. 2020;368:l6794. https:\/\/doi.org\/10.1136\/bmj.l6794.","journal-title":"BMJ"},{"issue":"3","key":"1561_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jaccao.2021.06.007","volume":"3","author":"C Bergom","year":"2021","unstructured":"Bergom C, Bradley JA, Ng AK, Samson P, Robinson C, Lopez-Mattei J, et al. Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification. JACC CardioOncol. 2021;3(3):343\u201359. https:\/\/doi.org\/10.1016\/j.jaccao.2021.06.007.","journal-title":"JACC CardioOncol"}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-024-01561-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-024-01561-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-024-01561-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T05:19:38Z","timestamp":1753161578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11764-024-01561-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1561"],"URL":"https:\/\/doi.org\/10.1007\/s11764-024-01561-y","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"assertion":[{"value":"20 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This observational study was exempt from institutional review board approval according to Dutch law.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Survivors who objected to the use of their medical data for research purposes were not included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Yolande Appelman has received a research grant from the Dutch Heart Foundation and from Abbott Cardiovascular. Olivier C. Manintveld has participated in advisory boards of, and\/or has received speaker allowances from Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Novartis and Vifor Pharma. The other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}